ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at-risk of complications.The company is based in Sydney and Melbourne, Australia and it has secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed.